Espinosa Zacarías J, Gutiérrez Moctezuma J, Villegas Peña H, Olmos G De Alba G
Servicio de Neurología Pediátrica, Centro Médico Nacional 20 de Noviembre del ISSSTE, México DF, México.
Rev Neurol. 2002;34(9):816-9.
Several mechanisms have been found to be involved in the development of malignant epileptic syndromes in childhood and an immunological component has been shown in experimental studies of epilepsy. The effect of intravenous immunoglobulin (IgIV) has been reported in various cases of epilepsy which were difficult to control.
To show the usefulness of IgIV in West s syndrome (WS) and Lennox Gastaut syndrome (LGS) which were difficult to control.
We selected five patients who fulfilled the criteria for WS and LGS which were difficult to control. They were given IgIV for five days and subsequently six fortnightly doses of 0.5 g/kg/day. We recorded data on sex, age, onset of the disorder and laboratory investigations, including blood and cerebrospinal fluid (CSF) immunoglobulin levels.
Four girls with symptomatic WS and one boy with LGS as a symptom of a neuro infection. Treatment was started at the age of 8 14 months. The spasms varied between 204 and 1,074 in 24 hours, and were markedly reduced after IgIV was given. The IgG in the CSF rose as the number of spasms fell (p< 0.05).
There was a satisfactory response to treatment, as reported in previous publications. It is a coadjuvant treatment for cases which are difficult to control and may also be useful in cases of symptomatic epilepsy where goods results are also obtained.
已发现多种机制参与儿童恶性癫痫综合征的发生发展,并且在癫痫的实验研究中已显示出免疫成分。静脉注射免疫球蛋白(IgIV)在各种难以控制的癫痫病例中的作用已有报道。
证明IgIV在难以控制的韦斯特综合征(WS)和 Lennox-Gastaut 综合征(LGS)中的有效性。
我们选择了 5 例符合难以控制的 WS 和 LGS 标准的患者。他们接受了 5 天的 IgIV 治疗,随后每两周给予 6 次剂量为 0.5 g/kg/天的治疗。我们记录了性别、年龄、疾病发作情况以及实验室检查数据,包括血液和脑脊液(CSF)免疫球蛋白水平。
4 名患有症状性 WS 的女孩和 1 名患有作为神经感染症状的 LGS 的男孩。治疗在 8 至 14 个月龄时开始。痉挛在 24 小时内变化范围为 204 至 1074 次,在给予 IgIV 后明显减少。CSF 中的 IgG 随着痉挛次数的减少而升高(p<0.05)。
如先前出版物所报道,治疗反应令人满意。它是一种针对难以控制病例的辅助治疗方法,在有良好效果的症状性癫痫病例中可能也有用。